2161.Hk
The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
Business. The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
The company maintains a strong capital structure, with a debt-to-equity ratio of 0.16, indicating a relatively low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.61, suggesting it has sufficient short-term assets to cover its liabilities, though not in excess. The company's return on equity of 18.23% and return on assets of 12.77% reflect a solid profitability profile, outperforming the typical expectations for the industry.
In terms of profitability, the company's operating income of 246.06 million HKD and net income of 197.26 million HKD demonstrate a healthy margin, with gross profit of 413.71 million HKD contributing to a strong bottom line. These figures suggest the company is effectively managing its costs and generating returns that are in line with or above industry norms.
The company's geographic and segment exposure is not explicitly detailed in the available data, but its revenue concentration is implied to be within the drug retailing segment, as this is the primary activity disclosed. There is no indication of significant diversification across multiple geographic regions or business lines.
Looking at the growth trajectory, the company's revenue of 782.29 million HKD indicates a stable performance, though specific growth rates or future projections are not provided in the data. The absence of detailed outlook data makes it difficult to assess the company's future growth potential with certainty.
The risk assessment highlights a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, suggesting that the company is not currently under pressure to issue additional shares, and there are no immediate concerns about equity dilution.
Recent events and filings do not provide specific details in the input data, so no recent developments or transcripts are available for analysis. The company's financial health appears to be stable, with no major red flags in the latest financial snapshot.
- The company has a strong profitability profile, with a return on equity of 18.23% and a return on assets of 12.77%.
- The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.16.
- The company's liquidity position is medium, with a current ratio of 1.61.
- The company's net cash position is negative after subtracting total debt, indicating a potential liquidity risk.
- The company's dilution risk is low, suggesting no immediate pressure to issue additional shares.
- **margin_outlook_rationale**: The company's gross profit margin is strong, indicating effective cost management and pricing power.
- **rd_outlook_rationale**: No specific data on research and development is provided, so the outlook is based on the company's overall profitability and financial health.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,29 |
| Revenue | —no estimate | —no estimate | 831,2M HKD |
| Operating income | —no estimate | —no estimate | 254,9M HKD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 2161.HK Market data — financials · 2026-05-26
- JBM (Healthcare) Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Patrick WongChief Executive Officer, Executive Director